SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 56.51-2.4%Dec 23 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (6075)4/2/2002 5:54:50 PM
From: Tomato   of 52153
 
Peter,

Thanks for the thoughtful reply. I keep thinking about Peter Lynch's first book (I think it was his first one) where he uses the approval of Tagamet as an example of how to invest. I don't have the book here but I recall he had a chart of Smith Kline (?) which I think went up several times in a few years after the drug's approval. I think the message was that you could wait for the risk to be out of the stock and still make a lot of money. But I guess if it were that easy to figure out everyone would just buy a stock after a blockbuster drug is approved. <g>

Wayne
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News